Your browser doesn't support javascript. This means that the content or functionality of our website will be limited or unavailable. If you need more information about Vinnova, please contact us.

Development of CMTM6 inhibitors: Modulation of PDL1 for cancer treatment

Reference number
Coordinator Adlego Biomedical AB
Funding from Vinnova SEK 142 550
Project duration March 2018 - January 2020
Status Completed
Venture Eurostars

Last updated 20 March 2019

Reference number 2018-00582

Page statistics